Qurient

Innovation for
Unmet
Medical
Needs

Global Leader
of Network
R&D

Clinical & non-clinical
pipeline with
Global
standard

Notice

2026-10-01	큐리언트, 모카시클립과 TOP1i ADC 병용 시너지 논문 '사이언스 어드밴스' 게재
2026-09-30	Qurient Announces Publication in Science Advances Demonstrating Synergistic Effect of Selective CDK7 Inhibitor Q901 with TOP1 Inhibitor-Based ADCs
2026-09-28	큐리언트, 이중 페이로드 ADC 플랫폼 특허 국제출원…글로벌 플랫폼 사업 기반 강화
2026-09-04	“성장 과실은 주주의 몫으로”…큐리언트, 주주배정 유상증자로 연구개발 성과 가속
2026-08-28	”독성 극복부터 신규 페이로드까지”…큐리언트, 'ADC & Bioconjugate East Asia 2026'서 차세대 ADC 전략 발표

Company

Founded in 2008, Qurient takes a pioneering position in the newly emerging biotech industry in Korea. Qurient introduced a unique virtual biotech model, running R&D operations not only in clinical development phases, but also in early discovery research stage, named ‘Network R&D’ model.See More
Business philosophy

Innovation for unmet medical needs

Qurient’s mission is to provide innovation for unmet medical needs to help patients around the world. Through fulfilling the mission, Qurient will be able to create concrete value for its shareholders. See More
Pipeline

Qurient portfolio plan aims to achieve balanced innovation by strategic positioning of the R&D programs.See More
IR/PR

Dear Qurient shareholders

Qurient would like to share brief updates on current progress made on its portfolio programs. See More